ABSTRACT 125I-Labeled choleragen was bound to liposomes containing galactosyl-N-acetylgalactosaminyl-Nacetylneuraminyl)-galactosylglucosylceramide (GM,), but not in large amounts to ganglioside-free liposomes nor to those containing N-acetylneuraminylgalactosylglucosylceramide
.glucose only from GMI-liposomes. This choleragen-induced glucose release-from GMl4iposomes was relatively rapid for the first few minutes, then continued more slowly. The amount of glucose released from liposomes in 30 min was dependent on both the GM, content and choleragen concentration. Prior incubation of GMI-liposomes with anti-GM1 antiserum prevented the choleragen-dependent release of trapped glucose. After incubation of GMI-liposomes with choleragen, addition of anticholeragen antibodies and complement led to more extensive glucose release. Under these latter conditions a much smaller glucose release was observed also from liposomes containing GM1 or N-acetylneuraminylgalactosyl-N-acetylgalactosaminyl(N-acetylneuraminyl)galactosylglucosylceramide in the absence of choleragen. These releases were attributed to naturally-occurring antiganglioside antibodies in the antiserum and complement. Ganglioside-free liposomes did not release glucose in response to anticholeragen and complement. It appears that choleragen in the absence of other proteins binds specifically to liposomes containing GM, and can induce permeability changes.
It is believed that the biological effects of choleragen on mammalian cells which include those on water and chloride fluxes in the intestinal mucosa are mediated by cyclic AMP (1) . The initial events occur at the cell surface where the B subunits of the toxin bind to specific receptors which appear to be the monosialoganglioside galactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide (GM1) (2-6). Then, by mechanisms as yet unknown, the A subunit penetrates the cell membrane and activates adenylate cyclase (7) (8) (9) .
GMl-deficient transformed mouse fibroblasts which are unresponsive to choleragen became sensitized after binding of exogenous GM, (6) . Incorporation of comparable amounts of other gangliosides [N-acetylneuraminylgalactosylglucosylceramide (GM3), N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide (GM2), and N-acetylneuraminylgalactosyl -N -acetylgalactosaminyl -(N-acetylneuraminyl)-galactosylglucosylceramide (GD1a)I did not result in a Abbreviations: GMI, galactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide; GM3, N-acetylneuraminylgalactosylglucosylceramide; GM2, N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide; GD1a, N-acetylneuraminylgalactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl)-galactosylglucosylceramide. choleragen response (10) . Gangliosides have also been incorporated into liposomal model membranes (11) . The GM1 in these liposomes is immunologically reactive as evidenced by the specific complement-dependent release of trapped glucose that follows the addition of antiganglioside serum and complement (unpublished data). In the studies reported here, we have used such ganglioside-containing liposomes to demonstrate that the-interaction of choleragen with GM1, in the absence of other proteins, can produce changes in the permeability of the liposomal membrane.
EXPERIMENTAL PROCEDURES
The liposomes, prepared as described elsewhere (12), contained dimyristoyl-lecithin, cholesterol, and dicetyl phosphate in molar ratios of 2:1.5:0.22 (10 nmol of phospholipid per Ail of liposomes) plus gangliosides where indicated. The methods for measuring release of trapped glucose from liposomes in the presence of antiserum and complement have been reported (12) . These same methods, utilizing 0.5 ml of Tris-buffered glucose assay reagent and a total reaction volume of 1.0 ml, were adapted to the measurement of choleragen-induced glucose release in the absence of antiserum or complement. Antiserum to mixed gangliosides was obtained from a rabbit which 4 weeks earlier had received a single injection into the rear footpads and one subcutaneous site of an emulsion of mixed gangliosides (20 mg), methylated bovine serum albumin (0.75 mg), and Freund's complete adjuvant (0.5 ml). This antiserum contained high levels of activity [assessed as described in (11)] against GM1 and galactosyl-N-acetylgalactosaminyl-(N-acetylneuraminyl-Nacetylneuraminyl)-galactosylglucosylceramide (GD1b), and relatively lower activity against GD1a. Individual gangliosides were obtained as previously described (6, 13) . 125I-Labeled choleragen was prepared by the method of McFarlane (14), complement was prepared as described previously (15) . Choleragen was purchased from Schwarz/Mann. Antibodies against choleragen (lyophilized horse gamma globulin, 4470 units/ml) were obtained from US-Japan Cooperative Medical Science Program of National Institutes of Health. The antibodies, reconstituted in water, were dialyzed against 0.15 M NaCl. 125I (carrier-free) was obtained from New England Nuclear Corp.
RESULTS
As shown in Table 1 , incorporation of GM1 into liposomes markedly increased their capacity to bind 125I-labeled choleragen; approximately 40% of the total radioactivity was bound to the GM1-liposomes. With the same conditions, the other glycolipids tested did not have this effect. To determine the effect of choleragen on the liposomes. they were prepared with glucose entrapped as previously described (12) . In the absence of choleragen, liposomes (with or without gangliosides) released only about 2% of the trapped glucose in 30 min (Fig. 1) . Choleragen had no significant effect on the release of glucose from liposomes without ganglioside or those containing GDia but markedly increased release from liposomes containing GM, (Fig. 1) . The release of glucose was relatively rapid during the first few minutes after addition of choleragen and then continued more slowly (Fig. 1) . As shown in Fig. 2 , the amount of glucose released from GM1-liposomes in 30 min was dependent on choleragen concentration. The effect of choleragen on glucose release was also dependent on the GM1 content of the liposomes (Fig. 3) . After incubation of GM1-li-CM 8 . posomes with anti-GM, serum, choleragen-dependent glucose release was abolished (Fig. 4) . Separate experiments revealed that GM1 liposomes incubated with anti-GMI serum and complement, however, released approximately 60% of the trapped glucose.
Addition of anticholeragen antibodies and complement to GMI-liposomes previously incubated with choleragen (0.5-25 Alg/ml) markedly increased the amount of glucose released to about 55% (Fig. 5) . Anticholeragen antibodies plus complement had no effect on liposomes without ganglioside but caused some glucose release from GDla-liposomes (Fig. 5) . As can be seen in Fig. 5 , in the absence of choleragen, anticholeragen antibodies plus complement (guinea pig serum) released 22 or 28% of the trapped glucose from liposomes containing GD15 or GM1, respectively, but had no effect on ganglioside-free liposomes. Another source of complement (human serum) by itself also released some glucose from GM1-liposomes, and this was in- (1.5 Mag/Ml of liposomes) (0), GDia (1.5 Mg/Ml of liposomes) (M) or no ganglioside (0) were incubated with choleragen at the indicated concentration for 30 min in a volume of 0.855 ml. Anticholeragen antibodies (about 100 units, 25 Ml) then were added, followed 10 min later by 0.12 ml of guinea pig serum (complement). Glucose release was determined 30 min later. Liposomes (4.7 Ml) were incubated with or without choleragen, (12.5 Mg in experiment 1 and 75 ,g in experiment 2) for 30 min at room temperature in a total volume of 0.855 ml. Anticholeragen antibody (about 100 units, 25 Ml) was then added where indicated and the incubation continued for 10 min. Complement (0.12 ml of human serum) was added to all samples and the incubation continued for 30 min prior to determining glucose release.
(globoside I) was inhibited by addition of choleragen and anticholeragen antibodies.
DISCUSSION
Liposomal model membranes have been used to study the interaction of antibodies and complement with antigens (16, 17) . Alving et al. (11) have shown that antiganglioside serum plus complement causes perturbation of the lamellar organization of liposomes containing gangliosides as evidenced by the release of trapped glucose. Choleragen is believed to bind to cells through the interaction of its B subunit with GM1 on the surface of the plasma membrane (2) (3) (4) (5) (6) . We have previously demonstrated that incorporation of exogeneous GM1 into GMl-deficient transformed mouse fibroblasts which are unresponsive to choleragen induces choleragen responsiveness (6) . Although this finding is consistent with the postulates of van 
